These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15346252)

  • 1. Past, present, and future hepatitis C treatments.
    Foster GR
    Semin Liver Dis; 2004; 24 Suppl 2():97-104. PubMed ID: 15346252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapies for the treatment of chronic hepatitis C.
    Idéo G; Bellobuono A
    Curr Pharm Des; 2002; 8(11):959-66. PubMed ID: 11945142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future treatment of hepatitis C.
    Manns MP; Cornberg M; Wedemeyer H
    Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C47-51. PubMed ID: 11293180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
    van Leusen R; Adang RP; de Vries RA; Cnossen TT; Konings CJ; Schalm SW; Tan AC
    Nephrol Dial Transplant; 2008 Feb; 23(2):721-5. PubMed ID: 18042614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.
    Hügle T; Cerny A
    Rev Med Virol; 2003; 13(6):361-71. PubMed ID: 14625884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future trends in managing hepatitis C.
    McHutchison JG; Dev AT
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S51-61. PubMed ID: 15081103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
    Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
    Ferenci P
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):157-74. PubMed ID: 16557187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.